ARANSCIA Trademark

Trademark Overview

On Friday, August 5, 2022, a trademark application was filed for ARANSCIA with the United States Patent and Trademark Office. The USPTO has given the ARANSCIA trademark a serial number of 97537158. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Friday, March 21, 2025. This trademark is owned by AccessDx Laboratory, LLC. The ARANSCIA trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Medical services, namely, providing medical information in the field of genomics, medical diagnostic testing, clinical testing, precision medicine, and medical consultation services in the nature of presenting clinical risk insights and recommendations of customized therapies based on diagnostic testing, clinical decision support, clinical outcomes, and population health management; the aforementioned being provided via clinical software and none being for conducting clinical trial for others, clinical and medical research, providing scientific research in the field of clinical trials, conducting pharmaceutical clinical trials for others, research on the subject of pharmaceuticals, consultancy in relation to scientific research, scientific consultancy services, consulting services in the fields of biotechnology pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics, pharmaceutical research and development, research and development of pharmaceutic...
aranscia

General Information

Serial Number97537158
Word MarkARANSCIA
Filing DateFriday, August 5, 2022
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateFriday, March 21, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 21, 2024

Trademark Statements

Goods and ServicesMedical services, namely, providing medical information in the field of genomics, medical diagnostic testing, clinical testing, precision medicine, and medical consultation services in the nature of presenting clinical risk insights and recommendations of customized therapies based on diagnostic testing, clinical decision support, clinical outcomes, and population health management; the aforementioned being provided via clinical software and none being for conducting clinical trial for others, clinical and medical research, providing scientific research in the field of clinical trials, conducting pharmaceutical clinical trials for others, research on the subject of pharmaceuticals, consultancy in relation to scientific research, scientific consultancy services, consulting services in the fields of biotechnology pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics, pharmaceutical research and development, research and development of pharmaceuticals

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, August 27, 2022
Primary Code044
First Use Anywhere DateWednesday, December 21, 2022
First Use In Commerce DateThursday, January 5, 2023

Trademark Owner History

Party NameAccessDx Laboratory, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressHouston, TX 77025
Party NameAccessDx Laboratory, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressHouston, TX 77025

Trademark Events

Event DateEvent Description
Tuesday, August 9, 2022NEW APPLICATION ENTERED
Saturday, August 27, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, October 19, 2022ASSIGNED TO EXAMINER
Wednesday, October 19, 2022NON-FINAL ACTION WRITTEN
Wednesday, October 19, 2022NON-FINAL ACTION E-MAILED
Wednesday, October 19, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 19, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 19, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 20, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 8, 2023FINAL REFUSAL WRITTEN
Thursday, June 8, 2023FINAL REFUSAL E-MAILED
Thursday, June 8, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, September 8, 2023TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, September 8, 2023EXPARTE APPEAL RECEIVED AT TTAB
Friday, September 8, 2023JURISDICTION RESTORED TO EXAMINING ATTORNEY
Friday, September 8, 2023EX PARTE APPEAL-INSTITUTED
Tuesday, January 30, 2024ASSIGNED TO LIE
Tuesday, January 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 8, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 8, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 11, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, April 11, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, April 11, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, April 11, 2024EXAMINER'S AMENDMENT ENTERED
Friday, April 12, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, April 12, 2024EXPARTE APPEAL TERMINATED
Wednesday, May 1, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 21, 2024PUBLISHED FOR OPPOSITION
Tuesday, May 21, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 16, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 16, 2025SOU EXTENSION 1 FILED
Thursday, January 16, 2025USE AMENDMENT FILED
Thursday, January 16, 2025TEAS STATEMENT OF USE RECEIVED
Thursday, January 16, 2025SOU TEAS EXTENSION RECEIVED
Friday, March 21, 2025STATEMENT OF USE PROCESSING COMPLETE
Friday, March 21, 2025SOU EXTENSION 1 GRANTED
Friday, March 21, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, March 21, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

aranscia clinical research medical testing services pharmaceutical development scientific others trials